(eleventh 2018) According to the results of the monitoring and evaluation, in order to further ensure the safety of public drug use, the State Administration of drug administration decided to revise the nonprescription drug instructions of menthol activating collaterals ointment [adverse reactions], [taboos] and [cautions]. The following items are now announced as follows: 1. All Mint activating collaterals should be submitted to the State Administration of drug administration before June 20, 2018, in accordance with the provisions of the regulations on drug registration and management, according to the revised requirements of the non prescription drug instructions of mint plaster (see Annex), and the supplementary application for the revision of the instructions. Amendments to the contents of drug labelling shall be revised together, and the contents of the instructions and labels should be consistent with the original approval. The production of pharmaceuticals from the date of filing of the supplementary application shall not continue to use the instructions of the original drugs. The non prescription drug production enterprises of mint and activating collaterals should take effective measures to do a good job of propaganda and training of the problem of the use and safety of menthol activating collaterals ointment, and guide the rational use of medicine for doctors and patients. Three. Peppermint activating cream is an over-the-counter medicine. Patients should read Mints cream paste before medication. Enclosureuff1a Revised requirements for non prescription drug instructions for Mentha activating collaterals ointment 1. [adverse reactions] increase the following items: This product has reports of rash and itching. Two, taboo items add the following contents: 1. children under two years old and pregnant women are prohibited. 2. it is forbidden for those who are allergic to this product and its components. Three, [note] amendment to: after first items, the increase of 2. products containing Methylis salicylas, external use can also be absorbed into the blood through the skin, for patients taking warfarin drugs excessive use of the drug, there may be a risk of bleeding. 3. children with cold, chicken pox or fever should avoid using Methylis salicylas products. 4. patients with hereditary glucose -6- phosphate dehydrogenase deficiency and those who are allergic to salicylic acid should be cautious. The rest of the serial number is postponed. The source of this article: editor of Chinese medicine information responsibility: Huang Jia _NNB6466 1. [adverse reactions] add the following contents: Two. [taboo] add the following: Three. [note] the item is amended to be: After first, 2. products contain Methylis salicylas, and external use can also be absorbed into the blood by skin. For patients taking warfarin drugs, the drug may be overused, and the risk of bleeding may be caused. 3. children with cold, chicken pox or fever should avoid using Methylis salicylas products. 4. patients with hereditary glucose -6- phosphate dehydrogenase deficiency and those who are allergic to salicylic acid should be cautious. The rest of the serial number is postponed.